OxFORD Asset Management LLP raised its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 20.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,586 shares of the medical instruments supplier’s stock after buying an additional 3,020 shares during the quarter. OxFORD Asset Management LLP owned about 0.09% of LeMaitre Vascular worth $549,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Dimensional Fund Advisors LP raised its stake in LeMaitre Vascular by 4.4% during the second quarter. Dimensional Fund Advisors LP now owns 968,232 shares of the medical instruments supplier’s stock valued at $30,228,000 after buying an additional 40,767 shares during the last quarter. Vanguard Group Inc. raised its stake in LeMaitre Vascular by 23.5% during the second quarter. Vanguard Group Inc. now owns 815,580 shares of the medical instruments supplier’s stock valued at $25,462,000 after buying an additional 155,249 shares during the last quarter. Conestoga Capital Advisors LLC raised its stake in LeMaitre Vascular by 45.8% during the second quarter. Conestoga Capital Advisors LLC now owns 565,069 shares of the medical instruments supplier’s stock valued at $17,641,000 after buying an additional 177,379 shares during the last quarter. Thomson Horstmann & Bryant Inc. raised its stake in LeMaitre Vascular by 1.8% during the second quarter. Thomson Horstmann & Bryant Inc. now owns 365,977 shares of the medical instruments supplier’s stock valued at $11,425,000 after buying an additional 6,638 shares during the last quarter. Finally, Northern Trust Corp raised its stake in LeMaitre Vascular by 9.8% during the second quarter. Northern Trust Corp now owns 239,671 shares of the medical instruments supplier’s stock valued at $7,483,000 after buying an additional 21,473 shares during the last quarter. Institutional investors and hedge funds own 66.34% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/oxford-asset-management-llp-buys-3020-shares-of-lemaitre-vascular-inc-lmat/1640604.html.

In related news, Director Lawrence J. Jasinski sold 2,030 shares of the firm’s stock in a transaction on Thursday, August 17th. The stock was sold at an average price of $34.23, for a total value of $69,486.90. Following the completion of the transaction, the director now owns 8,333 shares in the company, valued at approximately $285,238.59. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman George W. Lemaitre sold 58,700 shares of the firm’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $33.97, for a total value of $1,994,039.00. Following the completion of the transaction, the chairman now owns 3,471,808 shares of the company’s stock, valued at approximately $117,937,317.76. The disclosure for this sale can be found here. In the last quarter, insiders have sold 373,121 shares of company stock valued at $12,825,992. Company insiders own 23.70% of the company’s stock.

Shares of LeMaitre Vascular, Inc. (LMAT) opened at 38.21 on Thursday. The company has a market cap of $726.83 million, a price-to-earnings ratio of 54.59 and a beta of 0.67. LeMaitre Vascular, Inc. has a 12-month low of $18.55 and a 12-month high of $39.29. The firm has a 50 day moving average price of $37.59 and a 200-day moving average price of $32.03.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $0.23 EPS for the quarter, beating the consensus estimate of $0.17 by $0.06. LeMaitre Vascular had a return on equity of 15.02% and a net margin of 14.19%. The firm had revenue of $25.80 million during the quarter, compared to analyst estimates of $25.42 million. During the same quarter in the prior year, the business posted $0.14 EPS. The business’s revenue for the quarter was up 15.2% compared to the same quarter last year. On average, equities analysts expect that LeMaitre Vascular, Inc. will post $0.80 earnings per share for the current fiscal year.

LeMaitre Vascular declared that its Board of Directors has initiated a share buyback program on Thursday, July 27th that permits the company to repurchase $7.50 million in shares. This repurchase authorization permits the medical instruments supplier to reacquire up to 1.4% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

A number of research analysts have issued reports on the company. Canaccord Genuity reiterated a “hold” rating and set a $30.00 price objective on shares of LeMaitre Vascular in a research note on Monday, October 9th. Zacks Investment Research cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Thursday, September 28th. BidaskClub cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Wednesday, August 23rd. Stifel Nicolaus reiterated a “buy” rating and set a $32.00 price objective (up previously from $29.00) on shares of LeMaitre Vascular in a research note on Sunday, July 30th. Finally, Benchmark Co. cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Monday, July 10th. They noted that the move was a valuation call. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $32.00.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.